[Detection of EBV-LMP1 antibodies in sera and clinical significance in the patients with nasopharyngeal carcinoma].
To detect the levels of Epstein-Barr virus (EBV) latent membrane protein 1 Antibodies (LMP1-Ab) in nasopharyngeal carcinoma (NPC)sera and discuss the clinical significance of this test in diagnosis, prognosis, and immune-targeted therapy of NPC. Enzyme-linked immunosorbent assay (ELISA) and Western blot method were used to detect the LMP1-Ab levels in 61 NPC sera, 30 nasopharyngitis sera, and 55 normal sera. The relationship between the LMP1-Ab level and clinical and pathological features of NPC was analyzed. ELISA test showed that LMP1 antibodies level was significantly higher in nasopharyngeal carcinoma group than those in nasopharyngitis group and in healthy group and there were statistical significances (all P<0.05). In SNPC group, the LMP1-Ab level was not related to the pathological grade and cervical lymph node metastases (P>0.05). Western blot test revealed that the expression of LMP1 antibodies was higher in NPC sera than in nasopharyngitis sera and in normal sera. LMP1-Ab level was higher in nasopharyngeal carcinoma group than in nasopharyngitis group and in normal group. Therefore, LMP1 may be considered as a tumor correlated antigen to help the diagnosis and immune-targeted therapy of NPC.